<DOC>
	<DOCNO>NCT00381433</DOCNO>
	<brief_summary>AVI-4020 Injection , phosphorodiamidate Morpholino oligomer ( PMO ) , find cross blood-brain barrier study patient presumptive West Nile virus disease . AVI-4065 , design target HCV , also PMO ; ability cross blood-brain barrier unknown . In study , single dose AVI-4065 subcutaneously inject , sample collect determine drug cross blood-brain barrier . If , additional investigation could perform people severe form HCV disease brain affect .</brief_summary>
	<brief_title>Pharmacokinetic Study Single Dose AVI-4065 Cerebral Spinal Fluid</brief_title>
	<detailed_description>AVI-4020 Injection , phosphorodiamidate Morpholino oligomer ( PMO ) , find cross blood-brain barrier study patient presumptive West Nile virus disease . AVI-4065 , design target HCV , also PMO ; ability cross blood-brain barrier unknown . As incidence HCV disease grown , knowledge base disease likewise increase . Encephalopathy recognize consequence patient HCV infection . In study , single dose AVI-4065 subcutaneously inject , sample collect determine drug cross blood-brain barrier . If , additional investigation could perform people HCV disease brain affect .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<criteria>Adult males 18 year 64 year age ; Good general health ( evidence chronic condition , normal physical exam , vital sign within normal limit ; laboratory evaluation within normal range ) Signed date write informed consent form ; Willing participate study activity requirement , include effective contraception ( viz. , doublebarrier method ) 7day study surveillance period . Hematology , serum chemistry ( exclusive electrolyte ) , urinalysis laboratory test value &gt; 2 time upper limit normal anemia ( hemoglobulin &lt; 11 g/dL ) , leukopenia ( total white blood count &lt; 3,000/µL total neutrophil &lt; 1,500/ µL ) thrombocytopenia ( platelet &lt; 100,000/µL ) . Electrolytes coagulation value exceed normal range exclude . Body Mass Index ( BMI ) &gt; 35 . Calculated creatinine clearance ( Cockroft Gault Formula ) &lt; 70 mL/min , base age gender . Positive HIV1 HIV2 serology . Positive HCV serology and/or positive plasma HCVRNA status . Positive HBsAg HBcAb status . Solid hematopoetic organ transplant recipient . Active illness recent illness within 30 day first dose study drug . History follow : brain injury , neoplasm , chronic migraine headache , cancer , meningitis hydrocephalus . Usage prescribe , overthecounter illicit drug ( ) within 30 day study drug administration . Use herbal remedy and/or supplement discretion Investigator . Unwilling practice effective contraception study period . Participation clinical interventional trial within previous 6 month . Positive drug urine screen .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>HCV</keyword>
	<keyword>Hepatitis C virus</keyword>
</DOC>